- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04833582
A Study of ZN-c3 in Combination With Gemcitabine in Subjects With Osteosarcoma
November 10, 2023 updated by: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
A Phase 1/2 Dose Escalation and Dose Expansion Study of ZN-c3 in Combination With Gemcitabine in Adult and Pediatric Subjects With Relapsed or Refractory Osteosarcoma
This is a phase 1/2 study of ZN-c3 in combination with gemcitabine in adult and pediatric subjects with relapsed or refractory osteosarcoma.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
This is a phase 1/2 dose escalation and dose expansion study, evaluating the clinical activity and safety, pharmacodynamics, and pharmacokinetics of ZN-c3 in combination with gemcitabine in relapsed or refractory osteosarcoma.
Study Type
Interventional
Enrollment (Estimated)
84
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Project Director
- Phone Number: (858) 263-4333
- Email: info@zenopharma.com
Study Locations
-
-
-
Bordeaux, France, 33000
- Site 3604
-
Lyon, France, 69008
- Site 3601
-
Marseille, France, 13385
- Site 3602
-
Paris, France, 75248
- Site 3606
-
Toulouse, France, 31100
- Site 3605
-
-
-
-
California
-
Los Angeles, California, United States, 90095
- Site 0106
-
Oakland, California, United States, 94609
- Site 0124
-
Santa Monica, California, United States, 90403
- Site 0195
-
-
Florida
-
Gainesville, Florida, United States, 32610
- University of Florida College of Medicine
-
-
New York
-
New York, New York, United States, 10065
- Site 0105
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229
- Site 0107
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Site 0123
-
-
Tennessee
-
Memphis, Tennessee, United States, 38105
- Site 0193
-
Nashville, Tennessee, United States, 37332
- Site 0197
-
-
Texas
-
Houston, Texas, United States, 77030
- Site 0103
-
-
Virginia
-
Richmond, Virginia, United States, 23298
- Site 0188
-
-
Washington
-
Seattle, Washington, United States, 98195
- Site 0122
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
12 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age ≥ 12 years at the time of informed consent
- Bodyweight ≥ 40 kg
- Histologically documented relapsed or metastatic osteosarcoma.
- Must have measurable disease according to RECIST Guideline version 1.1 criteria.
- Adequate hematologic and organ function.
- Female subjects of childbearing potential and male subjects must agree to use an effective method of contraception per institutional standard prior to the first dose and for 6 months after study treatment discontinuation.
- Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
Exclusion Criteria:
- Unresolved toxicity of Grade >1 attributed to prior therapies (excluding: Grade ≤2 neuropathy, alopecia, or skin pigmentation)
- Prior therapy with a WEE1 inhibitor
- A serious illness or medical condition(s).
- Pregnant or lactating females. Females of childbearing potential with a positive serum pregnancy test <14 days to Day 1.
- Subjects with active (uncontrolled, metastatic) second malignancies or requiring therapy.
- 12-lead ECG demonstrating a corrected QT interval using Fridericia's formula (QTcF) of >470 ms, except for subjects with atrioventricular pacemakers or other conditions (e.g., right bundle branch block) that render the QT measurement invalid.
- History or current evidence of congenital or family history of long QT syndrome or Torsades de Pointes (TdP).
- Taking medications with a known risk of TdP.
- Administration of strong and moderate CYP3A4 inhibitors/inducers and strong and moderate P-gp inhibitors.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Combination ZN-c3 with Gemcitabine
|
ZN-c3 is an investigational drug.
Gemcitabine is an approved drug
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of dose-limiting toxicities (DLT) in DLT evaluable subjects and the incidence and severity of adverse events.
Time Frame: Through Cycle 1 (21 days) Phase 1
|
Through Cycle 1 (21 days) Phase 1
|
|
Event-free survival (EFS) at 18 weeks per RECIST (Response Evaluation Criteria in Solid Tumors) Guideline version 1.1.
Time Frame: During phase 2, at 18 weeks
|
EFS at 18 weeks is defined as time from study enrollment until date of disease progression, or detection of disease at a previously uninvolved site, or date of death of the subjects at 18 weeks.
|
During phase 2, at 18 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Event-free survival (EFS) per RECIST Guideline version 1.1.
Time Frame: At 12 months
|
EFS is defined as time from study enrollment until date of last contact, date of disease progression, or detection of disease at a previously uninvolved site, or date of death.
|
At 12 months
|
Median overall survival (OS) and OS at 12 months per RECIST Guideline version 1.1.
Time Frame: At 12 months
|
OS is defined as the time from date of first dosing until the date of death.
|
At 12 months
|
The frequency and severity of adverse events (AEs) and laboratory abnormalities per the National Cancer Institute Common Terminology (NCI CTCAE) version 5.0.lities.
Time Frame: Through completion, approximately 42 months
|
Through completion, approximately 42 months
|
|
Plasma pharmacokinetics (PK) maximum concentration (Cmax).
Time Frame: Through completion, approximately 42 months
|
Through completion, approximately 42 months
|
|
Plasma PK time to maximum concentration (Tmax).
Time Frame: Through completion, approximately 42 months
|
Through completion, approximately 42 months
|
|
Area under the plasma concentration versus timepoint curve (AUC last).
Time Frame: Through completion, approximately 42 months
|
Through completion, approximately 42 months
|
|
Terminal half-life of the plasma PK concentration.
Time Frame: Through completion, approximately 42 months
|
Through completion, approximately 42 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 1, 2021
Primary Completion (Actual)
August 30, 2023
Study Completion (Estimated)
December 30, 2023
Study Registration Dates
First Submitted
March 25, 2021
First Submitted That Met QC Criteria
April 2, 2021
First Posted (Actual)
April 6, 2021
Study Record Updates
Last Update Posted (Estimated)
November 14, 2023
Last Update Submitted That Met QC Criteria
November 10, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ZN-c3-003
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteosarcoma
-
Klinikum StuttgartKlinikum Kassel GmbH (COSS-Biobank)Not yet recruitingOsteosarcoma | High Grade Sarcoma | Recurrent Osteosarcoma | Bone Sarcoma | Undifferentiated Pleomorphic Sarcoma | Bone Tumor | Extraskeletal Osteosarcoma | Osseous Sarcoma | Parosteal Osteosarcoma | Osteoblastic Osteosarcoma | Chondroblastic Osteosarcoma | Fibroblastic Osteosarcoma | Conventional Osteosarcoma | Conventional... and other conditions
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Osteosarcoma | Refractory Osteosarcoma | Stage IV Osteosarcoma AJCC v7 | Stage IVA Osteosarcoma AJCC v7 | Stage IVB Osteosarcoma AJCC v7 | Metastatic OsteosarcomaUnited States, Canada, Puerto Rico
-
M.D. Anderson Cancer CenterRecruitingRecurrent Osteosarcoma | Refractory Osteosarcoma | Metastatic Osteosarcoma | Unresectable Osteosarcoma | Locally Advanced OsteosarcomaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)Not yet recruitingMetastatic Osteosarcoma | Localized Osteosarcoma | Unresectable Osteosarcoma | Resectable Osteosarcoma
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Osteosarcoma | Metastatic Osteosarcoma | Localized Osteosarcoma | Osteoblastic OsteosarcomaUnited States
-
National Cancer Institute (NCI)SuspendedMetastatic Osteosarcoma | Localized Osteosarcoma | High Grade Osteosarcoma | Secondary OsteosarcomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Ewing Sarcoma | Recurrent Osteosarcoma | Stage III Osteosarcoma AJCC v7 | Stage IV Osteosarcoma AJCC v7 | Stage IVA Osteosarcoma AJCC v7 | Stage IVB Osteosarcoma AJCC v7 | Metastatic Osteosarcoma | Metastatic Ewing Sarcoma | Unresectable Ewing Sarcoma | Unresectable OsteosarcomaFrance
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Osteosarcoma | Metastatic Osteosarcoma | Localized OsteosarcomaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Osteosarcoma | Metastatic Osteosarcoma | Localized OsteosarcomaUnited States
-
Sarcoma Alliance for Research through CollaborationActive, not recruitingOsteosarcoma | Osteosarcoma Recurrent | Osteosarcoma Metastatic | Osteosarcoma in ChildrenUnited States
Clinical Trials on ZN-c3
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityWithdrawnAnatomic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast Carcinoma | Stage III Fallopian Tube Cancer AJCC v8 | Stage III Ovarian Cancer AJCC v8 | Stage III Primary Peritoneal Cancer AJCC v8 | Stage IV Fallopian Tube Cancer AJCC v8 | Stage IV Ovarian Cancer AJCC v8 | Stage IV Primary... and other conditionsUnited States
-
K-Group Alpha, Inc., a wholly owned subsidiary...RecruitingAcute Myeloid Leukemia (AML)United States
-
K-Group, Beta, Inc., a wholly owned subsidiary...RecruitingHigh-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal CancerUnited States, Australia, France
-
Zentera Therapeutics HK LimitedRecruiting
-
K-Group, Beta, Inc., a wholly owned subsidiary...Recruiting
-
Joyce Liu, MDNational Cancer Institute (NCI); ZentalisNot yet recruitingUterine Cancer | Uterine Serous Carcinoma | Uterine CarcinomaUnited States
-
K-Group, Beta, Inc., a wholly owned subsidiary...RecruitingUterine Serous CarcinomaUnited States, Australia, Canada, Georgia
-
K-Group, Beta, Inc., a wholly owned subsidiary...PfizerRecruitingMetastatic Colorectal CancerSpain, Australia, United States, Italy, Germany, Poland, Hungary
-
K-Group, Beta, Inc., a wholly owned subsidiary...RecruitingOvarian Cancer | Fallopian Tube Cancer | Platinum-resistant Ovarian Cancer | Primary Peritoneal CarcinomaUnited States, France
-
The Netherlands Cancer InstituteNot yet recruitingMetastatic Colorectal Cancer